A variety of genetic predispositions, such as Lynch syndrome, is also implicated in bladder cancer. Even so, 30% of people with bladder cancer have no identifiable risk.

The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

LOS ANGELES, CA– In a groundbreaking achievement set to reshape the future of transplant medicine, Dr. Inderbir S. Gill has led the world’s first successful bladder transplant in a human being ...

The Army is bringing 28 Abrams tanks to Saturday's parade, each valued at approximately $5 million.

Amry tanks got a paint job before being moved to Washington D.C. for a parade on Donald Trump’s birthday, a retired general has revealed. Armor including M1A2 tanks, Stryker armored fighting ...

Pima County sheriff’s deputies arrested a well-known pedophilia conspiracist Monday morning on charges related to stealing and damaging water tanks belonging to a humanitarian group.

By Josh Beckerman UroGen Pharma shares surged after the company received Food and Drug Administration approval for bladder cancer drug Zusduri, previously known as UGN-102.

The massive military parade set to celebrate the US Army and President Trump’s birthday will include uniforms, arms, and vehicles from every major American conflict dating back to the Revolut… ...

U.S. military vehicles have appeared in the nation's capital ahead of a parade commemorating the Army's 250th anniversary.

Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC).